He also says this "But with the sales/ distribution performance so far Novartis must be wondering what they were thinking"
As for the performance?
I works extremely well, much better than Voltaren which is basically the same but without the TPM, Novartis have never given it a chance, bring it here to Oz and see how well it sells.
I reckon Novartis saw that it would cannabalise the sales of one of their big sellers.
Share Price After Award Decision, page-138
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add POH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.0¢ |
Change
0.000(0.00%) |
Mkt cap ! n/a | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| POH (ASX) Chart |
Day chart unavailable
